COX-2 inhibitors and risk of heart failure [3] (multiple letters)

Lancet

Volumn 364, Issue 9444, 2004, Pages 1486-1487

  Kammerl, Martin C ^a   Debler, Jens ^a   Riegger, Günter A ^a   Krämer, Bernhard K ^a   Mamdani, Muhammad ^b   Juurlink, David ^b   Laupacis, Andreas ^b   Wardle, E Nigel ^c  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^c NW1 8JS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB;

CLINICAL TRIAL; DISEASE PREDISPOSITION; DOSE RESPONSE; DRUG HALF LIFE; EDEMA; HEART FAILURE; HUMAN; HYPERTENSION; LETTER; PRIORITY JOURNAL; RISK FACTOR;

EID: 6944231391     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(04)17265-6     Document Type: Letter

References (5)

1. M Mamdani DN Juurlink DS Lee Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study Lancet 363 2004 1751 1756
2. MC Kammerl RM Nüsing W Richthammer BK Krämer A Kurtz Inhibition of COX-2 counteracts the effects of diuretics in rats Kidney Int 60 2001 1684 1691
3. K Höcherl D Endemann MC Kammerl HF Grobecker A Kurtz Cyclo-oxygenase-2 inhibition increases blood pressure in rats Br J Pharmacol 136 2002 1117 1126
4. JI Schwartz K Vandormael MP Malice Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal-salt diet Clin Pharmacol Ther 72 2002 50 61
5. BK Krämer MC Kammerl M Kömhoff Renal cyclooxygenase-2 (Cox-2): physiological, pathophysiological, and clinical implications Kidney Blood Press Res 27 2004 43 62